Literature DB >> 12780748

The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome.

Giuseppe Reimondo1, Piero Paccotti, Marco Minetto, Angela Termine, Guido Stura, Mauro Bergui, Alberto Angeli, Massimo Terzolo.   

Abstract

OBJECTIVE: It has been reported previously that the paired interpretation of the corticotrophin-releasing hormone (CRH) test and the 8-mg dexamethasone suppression test (HDDST) could have higher diagnostic power than any single test in the differential diagnosis of ACTH-dependent Cushing's syndrome. This finding has not been confirmed thereafter in large series. The aim of the present study has been to assess the operating characteristics of either the CRH test or the overnight HDDST and also to evaluate the potential utility of combining the interpretation of both tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. DESIGN AND PATIENTS: We have reviewed the medical records of 59 consecutive cases with ACTH-dependent Cushing's syndrome: 49 patients with proven Cushing's disease (CD) and 10 patients with proven ectopic ACTH syndrome (EAS). Univariate curves of the receiver operating characteristics (ROC) have been performed to define the best cut-off values, the sensitivity and the specificity for CRH and overnight HDDST. A comparison between the areas under the ROC curves has also been performed.
RESULTS: For the CRH test, the point on the ROC curve closest to 1 corresponded to a value of ACTH percentage increment of 50%[sensitivity 86% (72.6-94.8) and specificity 90% (55.5-98.3)]. The best threshold for cortisol percentage (30%) increment gave inferior results [sensitivity 61% (45.5-75.6) and specificity 70% (34.8-93.0)]. For the HDDST, the point on the ROC curve closest to 1 corresponded to a value of cortisol decrease from the baseline of 50%[sensitivity 77% (62.7-88.5), specificity 60% (26.4-87.6)]. The area under the ROC curve of the ACTH percentage increment after CRH was significantly greater than the area under the diagonal [0.9 (0.7-1.0), P= 0.0001]. Conversely, the area under the cortisol percentage decrement after dexamethasone was not different from that obtained by chance [0.7 (0.5-0.9), P= ns]. The area under the ROC curve of CRH is significantly greater than that of overnight HDDST (P = 0.03). A correct diagnosis has been achieved by the CRH test in 86.5% of cases and by the HDDST in 73% (P = 0.06). The combination of both tests has given a correct diagnosis in a significantly lower percentage of cases than the CRH test alone (69%, P= 0.04). The bilateral inferior petrosal sinus sampling (BIPSS) has been performed in 29 patients (24 CD, five EAS) who had negative imaging and/or discordant results of the noninvasive tests. Considering the criterion of a central to peripheral ACTH ratio > 3 after CRH stimulation, a correct diagnosis was achieved in all cases.
CONCLUSIONS: The present data suggest that the CRH is likely to be the most reliable noninvasive diagnostic procedure for the differential diagnosis of the ACTH-dependent Cushing's syndrome. The criterion for a diagnosis of EAS is an ACTH percentage increment lower than 50%. The use of a combination of tests is not recommended because it does not add valuable information and may even impair the outcome of the CRH test. Cases with discordant results in pituitary imaging and CRH test should undergo BIPSS. The validity of this approach, which is straightforward and easily applicable in clinical practice, should be verified in larger series.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780748     DOI: 10.1046/j.1365-2265.2003.01776.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  24 in total

1.  Characterisation of ACTH related peptides in ectopic Cushing's syndrome.

Authors:  Robert L Oliver; Julian R E Davis; Anne White
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

3.  Power spectrum scale invariance identifies prefrontal dysregulation in paranoid schizophrenia.

Authors:  Anca R Radulescu; Denis Rubin; Helmut H Strey; Lilianne R Mujica-Parodi
Journal:  Hum Brain Mapp       Date:  2011-05-12       Impact factor: 5.038

4.  Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome.

Authors:  Mattia Barbot; Laura Trementino; Marialuisa Zilio; Filippo Ceccato; Nora Albiger; Andrea Daniele; Anna Chiara Frigo; Rodica Mardari; Giuseppe Rolma; Marco Boscaro; Giorgio Arnaldi; Carla Scaroni
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

5.  Ectopic adrenocorticotropic hormone and corticotropin-releasing hormone co-secreting tumors in children and adolescents causing cushing syndrome: a diagnostic dilemma and how to solve it.

Authors:  Alexander S Karageorgiadis; Georgios Z Papadakis; Juliana Biro; Meg F Keil; Charalampos Lyssikatos; Martha M Quezado; Maria Merino; David S Schrump; Electron Kebebew; Nicholas J Patronas; Maya K Hunter; Mouhammad R Alwazeer; Lefkothea P Karaviti; Andrea E Balazs; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 6.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 7.  Adrenocortical hypertension.

Authors:  Angelo Capricchione; Nathaniel Winer; James R Sowers
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

8.  The role of non-invasive dynamic tests in the diagnosis of Cushing's syndrome.

Authors:  L Vilar; M C Freitas; L A Naves; V Canadas; J L Albuquerque; C A Botelho; C S Egito; M J Arruda; L M Silva; C M Arahata; R Agra; L H C Lima; M Azevedo; L A Casulari
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

9.  RELIABILITY OF THE CORTICOTROPIN RELEASING HORMONE STIMULATION TEST FOR DIFFERENTIATING BETWEEN ACTH DEPENDENT AND INDEPENDENT CUSHING SYNDROME.

Authors:  O Polat Korkmaz; B Karayel; M Korkmaz; O Haliloglu; S Sahin; E Durcan; M M Oren; P Kadioglu
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

10.  Is it Time for a New Approach to the Differential Diagnosis of ACTH-Dependent Cushing Syndrome?

Authors:  Lynnette K Nieman
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.